Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAXG in Pancreatic Ductal Adenocarcinoma (OINC)
NCT04480268Phase 4Recruiting
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jul 2020
- Primary completion
- Jan 2022
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of cisplatin, paclitaxel, capecitabine, gemcitabine in pancreatic ductal adenocarcinoma (PDAC), sponsored by IRCCS Ospedale San Raffaele. Started Jul 2020; status: recruiting.
02
Drugs
cisplatinpaclitaxelcapecitabinegemcitabine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04480268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04480268.